Geneoscopy's Erica Barnell on AI in Gastrointestinal Health Diagnostics

Erica Barnell is the co-founder and Chief Science Officer at Geneoscopy Inc., a clinical-stage diagnostic company working on early detection of colorectal cancer. Its technology analyzes RNA in stool samples to look for early warning signs of cancer, providing a non-invasive alternative to colonoscopies. Geneoscopy raised a $6.9m Series A in 2019; in 2020, its diagnostic device was awarded Breakthrough Device Designation from the FDA and Erica was listed in Forbes 30 Under 30, and in 2021 a peer-reviewed article with results of company’s mutlifactor RNA-FIT test was published in the journal Clinical and Translational Gastroenterology.

Erica is also an MD/PhD candidate at the Washington University School of Medicine with a PhD in Molecular Genetics and Genomics, where her thesis work was completed in the Griffith Lab at the McDonnell Genome Institute to advance bioinformatic tools in the precision oncology space. She joins Dave and Fully to discuss how AI is helping to detect colorectal cancer and other gastrointestinal health conditions.
We also get to talk poop jokes for the first time.